Skip to main content
Clinical Trials/NCT05795413
NCT05795413
Active, not recruiting
Not Applicable

Patient Quality of Recovery From Mastectomy With and Without PECS Block With Liposomal Bupivacaine

Endeavor Health1 site in 1 country800 target enrollmentApril 25, 2023

Overview

Phase
Not Applicable
Intervention
Mastectomy with PECS blocks
Conditions
Post Operative Pain
Sponsor
Endeavor Health
Enrollment
800
Locations
1
Primary Endpoint
Quality of Recovery 15 Survey
Status
Active, not recruiting
Last Updated
6 months ago

Overview

Brief Summary

This is a prospective observational study. Investigators want to understand post-operative recovery for patients undergoing mastectomy at NorthShore University HealthSystem. Some of these patients receive PECS blocks with Liposomal Bupivacaine and some do not receive a block. Investigators want to know whether patients who receive a block have better post operative recovery and pain control than patients who do not receive one. Investigators also want to understand whether PECS blocks with Liposomal Bupivacaine improves quality of recovery at 72 hours post operatively.

Detailed Description

Investigators plan to approach and consent 800 patients undergoing mastectomy, 400 with PECS blocks and 400 without. Investigators will assess their quality of recovery using the QoR 15 survey at 72 hours post operatively. In addition, investigators will also record VAS scores immediately postoperatively and at 24, 48, and 72 hours postoperatively. The study team will also calculate the total morphine equivalents (MMEs) required for each patient after 72 hours.

Registry
clinicaltrials.gov
Start Date
April 25, 2023
End Date
April 1, 2027
Last Updated
6 months ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Katharine Yao, MD

Chief, Division of Surgical Oncology Vice Chair, Research and Development

Endeavor Health

Eligibility Criteria

Inclusion Criteria

  • Must be female Must be \>18 years old and \< 90 years old Must be able to consent in English or Spanish May or may not have breast cancer (prophylactic mastectomy) Must be undergoing unilateral or bilateral mastectomy of any type May choose to proceed with or without breast reconstruction

Exclusion Criteria

  • Allergy to all narcotic or local anesthetic medications Intake of any chronic opioids or pain medications preoperatively for a chronic condition or chronic use.
  • Subjects who received PECS blocks but whose block failed or is deemed not effective by an anesthesia provider as indicated by postoperative evaluation exam.
  • Vulnerable subjects (children, prisoners, pregnant women)

Arms & Interventions

PECS Block with Liposomal Bupivacaine

The patients in this cohort will undergo a PECS block with Liposomal Bupivacaine before their mastectomy. Patients will receive Liposomal Bupivacaine in combination with 0.25% Bupivacaine in a 1:1 mixture for the purpose of post-operative pain control.

Intervention: Mastectomy with PECS blocks

PECS Block with Liposomal Bupivacaine

The patients in this cohort will undergo a PECS block with Liposomal Bupivacaine before their mastectomy. Patients will receive Liposomal Bupivacaine in combination with 0.25% Bupivacaine in a 1:1 mixture for the purpose of post-operative pain control.

Intervention: Liposomal bupivacaine

Outcomes

Primary Outcomes

Quality of Recovery 15 Survey

Time Frame: 72 hours post operatively

Patients will complete the quality of recovery 15 survey 72 hours after surgery. This is a scale from 0 to 150. A score of 150 indicates better post operative recovery.

Secondary Outcomes

  • Visual analog scale(72 hours post operatively)
  • Morphine milligram equivalents(72 hours post operatively)

Study Sites (1)

Loading locations...

Similar Trials